Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553792 | 0.76 | NPC1 (0.35) | ALDH1A1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL2073990 | 0.76 | HTR2A (0.36) | ALDH1A1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL4838387 | 0.76 | HTR2A (0.36) | ALDH1A1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL1375450 | 0.76 | NPC1 (0.35) | ALDH1A1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL15010759 | 0.76 | POLB (0.33) | ALDH1A1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL1198917 | 0.76 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL10785337 | 0.74 | POLB (0.33) | ALDH1A1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL621734 | 0.74 | ADRA2A (0.31) | — | |
| SCHEMBL3266678 | 0.72 | MEN1 (0.41) | ALDH1A1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL2734403 | 0.72 | NPC1 (0.37) | ALDH1A1MEN1KMT2AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12137606-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2024-11-05 | — | — | US | disclosed |
| US-11878013-B2 | Isoquinoline derivative, preparing method thereof, and pharmaceutical composition for preventing or treating autophagy related diseases containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-01-23 | — | — | US | disclosed |
| US-20230025531-A1 | Novel Isoquinoline Derivative, Preparing Method Thereof, and Pharmaceutical Composition for Preventing or Treating Autophagy Related Diseases Containing the Same as an Active Ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-01-26 | — | — | US | disclosed |
| US-20220123235-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2022-04-21 | — | — | US | disclosed |
| CN-108026042-B | Method for fluorinating a compound | 美国陶氏益农公司 | 2022-01-04 | — | — | CN | disclosed |
| EP-3331857-B1 | PROCESS FOR FLUORINATING COMPOUNDS | CORTEVA AGRISCIENCE LLC (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-2665342-B1 | COMPOSITION FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND ILLUMINATOR | MITSUBISHI CHEM CORP (JP) | 2021-03-03 | — | — | EP | disclosed |
| CN-106632112-B | Organic compound, charge transport material, composition, organic electroluminescent element, display device, and lighting device | 三菱化学株式会社 | 2020-10-09 | — | — | CN | disclosed |
| EP-3331857-A1 | PROCESS FOR FLUORINATING COMPOUNDS | Dow Agrosciences LLC (US) | 2018-06-13 | — | — | EP | disclosed |
| CN-108026042-A | Method for being fluorinated compound | 美国陶氏益农公司 | 2018-05-11 | — | — | CN | disclosed |
| WO-2005046712-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050090432-A1 | Macrocyclic isoquinoline peptide inhibitors of Hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-28 | — | — | US | disclosed |
| US-6867185-B2 | Inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1505963-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004094452-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-1455809-A2 | INHIBITORS OF HEPATITIS C VIRUS | Bristol-Myers Squibb Company (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20040106559-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
| US-20040038872-A1 | Inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003053349-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038872-A1 | Inhibitors of hepatitis C virus | HAVCR2, LIPC, ZC3HAV1 | ALDH1A1 576/4885MEN1 4624/4885KMT2A 4399/4885 |
| US-20050090432-A1 | Macrocyclic isoquinoline peptide inhibitors of Hepatitis C virus | VIP, QPCT, HCCS | ALDH1A1 4253/4885MEN1 2867/4885KMT2A 4284/4885 |
| US-20230025531-A1 | Novel Isoquinoline Derivative, Preparing Method Thereof, and Pharmaceutical Composition for Preventing or Treating Autophagy Related Diseases Containing the Same as an Active Ingredient | ATG7, TFEB, BECN1 | ALDH1A1 1651/4885MEN1 1069/4885KMT2A 2714/4885 |
| US-12137606-B2 | Organic electroluminescent materials and devices | RER1, OXSR1, C1R | ALDH1A1 2010/4885MEN1 2638/4885KMT2A 4017/4885 |
| US-20040106559-A1 | Hepatitis C virus inhibitors | HAVCR2, HCCS, RNASE1 | ALDH1A1 512/4885MEN1 4817/4885KMT2A 4220/4885 |
| US-20220123235-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | RER1, OXSR1, C1R | ALDH1A1 2010/4885MEN1 2638/4885KMT2A 4017/4885 |
| US-11878013-B2 | Isoquinoline derivative, preparing method thereof, and pharmaceutical composition for preventing or treating autophagy related diseases containing the same as an active ingredient | TFEB, ATG7, BECN1 | ALDH1A1 1390/4885MEN1 800/4885KMT2A 2755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.